X4 Pharmaceuticals, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDX4 Pharmaceuticals, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 70), indicating performance broadly in line with the market. Earnings contraction of 5% provides fundamental context to the price action. Investors should exercise caution due to high volatility (124% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.00 | +5.79% | ABOVE |
| 50 SMA | $4.09 | +3.53% | ABOVE |
| 100 SMA | $3.94 | +7.25% | ABOVE |
| 150 SMA | $3.90 | +8.48% | ABOVE |
| 200 SMA | $3.78 | +11.77% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is XFOR in an uptrend right now?
XFOR has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, XFOR is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is XFOR overbought or oversold?
XFOR's RSI (14) is 50. The stock is in neutral territory, neither overbought nor oversold.
Is XFOR outperforming the market?
XFOR has a Relative Strength (RS) Rating of 70 out of 99. XFOR is performing about average compared to the market.
Where is XFOR in its 52-week range?
XFOR is trading at $4.23, which is 88% of its 52-week high ($4.83) and 83% above its 52-week low ($1.35).
How volatile is XFOR?
XFOR has a Beta of 2.44 and 52-week volatility of 124%. It's more volatile than the S&P 500 - expect bigger swings.